✦ LIBER ✦

Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin’s lymphomas

✍ Scribed by I Çelik; A Kars; N Güler; I Barışta; G Tekuzman; Ö Özyılkan; M Hayran; D Fırat

Book ID: 117664109
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 35 KB
Volume: 34
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)10023-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of bisantrene in patients

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

✍ Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 239 KB

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s

A phase II trial of promace-cytabom in p

A phase II trial of promace-cytabom in previously untreated non-hodgkin's lymphoma of intermediate- or high-grade histology

✍ G. Rossi; M. R. Mariano; G. Arcangeli; V. Bonfanti; M. A. Capucci; P. Ferremi; P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB

the aggressive combination chemotherapy programme ProMACE-CytaBOM was used at a community-based hospital as primary treatment for non-Hodgkin's lymphoma (NHL) of intermediate or high-grade histology in Ann-Arbor stages IB-IV. The 53 patients entering the study represented 90 per cent of all consecut

A phase I/II trial of liposomal doxorubi

A phase I/II trial of liposomal doxorubicin (tlc-d99, myocet) in combination with cyclophosphamide, vincristine, and prednisone (comp) for newly diagnosed intermediate and high grade non-Hodgkin's lymphoma (nhl)

✍ A. Tulpule; B.M. Espina; N. Berman; L.H. Buchanan; W.D. Boswell; L. Welles; A.M. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Rituximab as first-line and maintenance

Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial

✍ John D Hainsworth 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Non-Hodgkin's lymphoma in elderly patien

Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate- or high-grade histology

✍ Bessell, E.M.; Coutts, A.; Fletcher, J.; Toghill, P.J.; Moloney, A.J.; Ellis, I. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 642 KB

A randomized trial of two types of adjuv

A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma

✍ J. Wagstaff; I. Todd; D. Deakin; P. Wilkinson; J. H. Scarffe; M. Harris; M. Jone 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 600 KB

This paper reports the 8-year results of comparing the use of two types of adjuvant chemotherapy following involved field radiotherapy for clinical stages I and II high-grade non-Hodgkin's lymphoma. Twenty-four patients received 6 weeks of VAP plus 2 years of oral maintenance chemotherapy, and 30 ha